Values First Advisors Inc. Makes New $62,000 Investment in Dyne Therapeutics, Inc. (NASDAQ:DYN)

Values First Advisors Inc. purchased a new stake in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) during the third quarter, HoldingsChannel reports. The institutional investor purchased 1,720 shares of the company’s stock, valued at approximately $62,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Nisa Investment Advisors LLC raised its position in Dyne Therapeutics by 904.1% in the 2nd quarter. Nisa Investment Advisors LLC now owns 743 shares of the company’s stock worth $26,000 after buying an additional 669 shares during the last quarter. Amalgamated Bank grew its stake in shares of Dyne Therapeutics by 39.9% in the second quarter. Amalgamated Bank now owns 2,792 shares of the company’s stock worth $99,000 after acquiring an additional 796 shares during the period. Ameritas Investment Partners Inc. lifted its position in Dyne Therapeutics by 28.0% during the first quarter. Ameritas Investment Partners Inc. now owns 5,896 shares of the company’s stock valued at $167,000 after purchasing an additional 1,291 shares during the period. Public Employees Retirement Association of Colorado purchased a new stake in Dyne Therapeutics in the second quarter worth approximately $203,000. Finally, Farallon Capital Management LLC bought a new stake in Dyne Therapeutics in the 2nd quarter worth approximately $212,000. Institutional investors own 96.68% of the company’s stock.

Insider Activity at Dyne Therapeutics

In other Dyne Therapeutics news, CEO John Cox purchased 32,000 shares of the company’s stock in a transaction on Wednesday, September 4th. The stock was acquired at an average cost of $33.04 per share, for a total transaction of $1,057,280.00. Following the purchase, the chief executive officer now directly owns 8,000 shares of the company’s stock, valued at $264,320. This trade represents a -100.00 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In related news, SVP Richard William Scalzo sold 1,390 shares of the business’s stock in a transaction dated Wednesday, September 18th. The stock was sold at an average price of $34.55, for a total value of $48,024.50. Following the sale, the senior vice president now directly owns 98,568 shares in the company, valued at approximately $3,405,524.40. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO John Cox purchased 32,000 shares of the business’s stock in a transaction on Wednesday, September 4th. The shares were purchased at an average price of $33.04 per share, with a total value of $1,057,280.00. Following the acquisition, the chief executive officer now directly owns 8,000 shares in the company, valued at $264,320. This represents a -100.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last 90 days, insiders have sold 158,975 shares of company stock valued at $5,693,789. 20.77% of the stock is owned by company insiders.

Dyne Therapeutics Price Performance

Shares of NASDAQ DYN opened at $30.73 on Friday. The stock has a market cap of $2.69 billion, a PE ratio of -7.74 and a beta of 1.05. Dyne Therapeutics, Inc. has a 1 year low of $6.40 and a 1 year high of $47.45. The firm has a fifty day moving average price of $36.34 and a 200-day moving average price of $34.66.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings results on Monday, August 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.02. On average, research analysts expect that Dyne Therapeutics, Inc. will post -2.96 EPS for the current year.

Wall Street Analysts Forecast Growth

DYN has been the topic of a number of research reports. Piper Sandler restated an “overweight” rating and issued a $53.00 price target on shares of Dyne Therapeutics in a research note on Monday, September 23rd. JPMorgan Chase & Co. downgraded Dyne Therapeutics from an “overweight” rating to a “neutral” rating and cut their price target for the company from $43.00 to $35.00 in a research note on Thursday. StockNews.com cut shares of Dyne Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, September 16th. Oppenheimer restated an “outperform” rating and set a $55.00 target price on shares of Dyne Therapeutics in a research report on Tuesday, September 3rd. Finally, HC Wainwright reiterated a “buy” rating and issued a $55.00 price target on shares of Dyne Therapeutics in a research report on Wednesday, September 4th. One research analyst has rated the stock with a sell rating, one has given a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $50.60.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.